Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 543Neoplasms 449Carcinoma, Non-Small-Cell Lung 410Prostatic Neoplasms 334Colorectal Neoplasms 315Lung Neoplasms 261Multiple Myeloma 229Neoplasm Metastasis 190Pancreatic Neoplasms 186Leukemia, Myeloid, Acute 183Ovarian Neoplasms 178Melanoma 147Squamous Cell Carcinoma of Head and Neck 140Carcinoma, Hepatocellular 116Recurrence 115Head and Neck Neoplasms 114Carcinoma, Renal Cell 112Lymphoma 111Stomach Neoplasms 110Endometrial Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Glioblastoma 108Brain Neoplasms 106Lymphoma, Non-Hodgkin 105Uterine Cervical Neoplasms 100Triple Negative Breast Neoplasms 97Urinary Bladder Neoplasms 95Hematologic Neoplasms 91Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Large B-Cell, Diffuse 84

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × 30 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡